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Abstract
Lung cancer causes more deaths than breast, colorectal and prostate cancers combined. Despite 
major advances in targeted therapy in a subset of lung adenocarcinomas, the overall 5-year 
survival rate for lung cancer worldwide has not significantly changed for the last few decades. 
DNA repair deficiency is known to contribute to lung cancer development. In fact, human 
polymorphisms in DNA repair genes such as xeroderma pigmentosum group C (XPC) are highly 
associated with lung cancer incidence. However, the direct genetic evidence for the role of XPC 
for lung cancer development is still lacking. Mutations of the Kirsten rat sarcoma viral oncogene 
homolog (Kras) or its downstream effector genes occur in almost all lung cancer cells, and there 
are a number of mouse models for lung cancer using these mutations. Using activated Kras, 
KrasLA1, as a driver for lung cancer development in mice, we showed for the first time that mice 
with KrasLA1 and Xpc knockout had worst outcomes in lung cancer development, and this 
phenotype was associated with accumulated DNA damage. Using cultured cells, we demonstrated 
that induced expression of oncogenic KRASG12V led to increased levels of reactive oxygen 
species (ROS) as well as DNA damage, and both can be suppressed by anti-oxidants. Thus, it 
appears that XPC may help repair DNA damage caused by KRAS-mediated production of ROS.
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Introduction
Lung cancer is the leading cause of cancer-related death worldwide, claiming more than 1.5 
million lives every year (which exceeds the combined mortality from breast, prostate and 
colorectal cancers) (Siegel et al., 2015). Lung cancer is understood to be a largely 
environmental disease, with cigarette smoking as a major (but not the only) risk factor. 
Patients with advanced stage of lung cancer, which represents 75% of all new cases, have a 
median survival time of only 10 months. Thus, understanding the molecular basis of lung 
cancer has been a major focus in cancer research.
There are a number of genetic alterations in lung cancer, and specific gene mutations are 
associated with a given subset of tumors (Cooper et al., 2013). For example, mutations of 
RAS or its upstream/downstream effectors occur almost in every lung cancer cell, and 
expression of activated KRAS in mice has been a robust model for lung cancer 
development, particularly non-small cell lung cancer (NSCLC). Furthermore, targeted 
therapy towards growth factor receptor gene mutations in NSCLC has significantly 
improved the quality of life in a subset of lung cancer patients (Robert et al., 2015; Thomas 
et al., 2015; Thress et al., 2015; Tricker et al., 2015; Ugurel et al., 2015; Weber et al., 2015; 
Yang et al., 2015a, 2015b). In addition, gene mutations in the p53 and RB/p16 pathways are 
common in lung cancer (Cooper et al., 2013).
Amounting evidence indicate that decreased expression of DNA repair protein XPC, which 
is responsible for global nucleotide excision repair (NER), is correlated with poor outcomes 
of lung cancer patients (Wu et al., 2007a). Xpc deficient mice also develop several types of 
cancer, such as lung, liver and skin cancers, after exposure to carcinogens or UV irradiation 
(Cheo et al., 1996; Berg et al., 1998; Cheo et al., 2000; Friedberg et al., 2000; Hollander et 
al., 2005). Because most of these mice developed tumors after 15 months, it has been 
suggested that XPC’s effects in tumor development were through regulation of NER system. 
In human population studies, Xpc Lys939Gln polymorphism is highly associated with 
development of lung cancer (Hu et al., 2005; Lee et al., 2005; Vogel et al., 2005; Matakidou 
et al., 2006; Jin et al., 2014). Despite the significance of XPC in lung cancer, there is still no 
direct genetic evidence to demonstrate the significance of XPC for lung cancer development. 
XPC was originally regarded as nucleotide excision repair molecule, but recent studies have 
shown that NER factors including XPC contribute to the repair of oxidative DNA lesions 
including 8-oxo-7,8-dihydroguanine (Menoni et al., 2012; Parlanti et al., 2012). It is not 
known how XPC is involved in cancer development.
In this study, we use mutant Kras-driven lung cancer model to test the effect of XPC 
deficiency on DNA damage, tumor development and mouse survival in mice. We also tried 
to identify the underlying molecular mechanisms using inducible expression of activated 
RAS in cultured cells.
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RESULTS
XPC deficiency promotes KRAS-mediated tumor development
To understand the role of XPC in lung cancer development, we examined Kras-mediated 
tumor development in mice with or without Xpc expression. In KrasLA1 mice, we found all 
mice developed tumor in the lung, which is similar to a previous report (Johnson et al., 
2001). The phenotype became more severe when Xpc gene was knocked out (Fig. 1 and 2). 
Based on the survival time, we found that KrasLA1/ Xpc−/−mice all died whereas less than 
40% of Xpc+/+/KrasLA1 mice died at 40 weeks. As expected, Xpc−/−mice without KrasLA1 
and the control mice had no mortality within the same period of time (Fig. 1).
Further examination indicated that all dead mice had lung cancer and aberrant growth in 
intestine and skin epithelium. For lung cancer, we observed different stages of tumor, 
including adenomas, adenocarcinomas as well as mixed tumor types (Fig. 2). The tumors 
were mostly adenocarcinomas in 2-month-old Xpc−/−/KrasLA1 mice (Fig. 2D) whereas the 
same aged mice with KrasLA1 had mostly adenomas (Fig. 2C). For Xpc−/−mice, we did not 
observe any tumors even after one year, which is consistent with a previous report that 
Xpc−/−mice only develop spontaneous lung tumors at an old age ( > 15 months) after 
exposure to carcinogens (Cheo et al., 1997, 2000; Hollander et al., 2005). These data suggest 
that unrepaired oncogenic gene mutations resulting from the defective DNA repair system in 
Xpc−/− mice may be responsible for tumor development. Based on BLISS independence 
analysis, we observed a more than additive effect (synergy) between Xpc loss and oncogenic 
Kras gene expression in development in Aberrant crypt foci (ACF; see Fig. S1 for a typical 
ACF image). We found that Xpc−/−KrasLA1 mice, on average, had >15 ACF whereas 
KrasLA1mice had only 5 ACF on average (Fig. 3). No ACF lesions were found in Xpc−/−or 
the control mice within the same period of time. Taken together, these data indicate that Xpc 
deficiency accelerates KrasLA1-mediated tumor development.
Effects of Xpc on production of ROS and genomic DNA damage
Next we tried to determine the molecular basis by which XPC deficiency promotes Kras-
mediated tumor development. COMET assay is a reliable way to measure DNA damage 
(Dusinska and Collins, 2008). Using COMET assay, we found that Xpc loss results in 
elevated levels of DNA damage, including single and double strand breaks in both the 
tumor-prone lung tissue (Fig. 4) and lymphocytes (data not shown). We further confirmed 
elevated frequency of Hprt gene mutation in cells with XPC knockout cells, suggesting that 
an increased DNA damage is associated with an elevated gene mutation rate (Fig. S2). The 
effect of Xpc loss on DNA damages is consistent with the role of XPC in DNA repair in 
previous studies (Friedberg et al., 2000).
To determine the effect of Kras expression on DNA damage in lung tissues, we performed 
COMET assay, and found that KrasLA1 positive mice had an elevated level of DNA damage 
in the lung tissue (Fig. 4). More interestingly, Xpc−/−KrasLA1 mice had much more damaged 
DNAs in the lung tissues than either Xpc−/−or KrasLA1 mice (Fig. 4). Based on BLISS 
analysis (Gu et al., 2013), we found that the DNA damage in the Xpc−/−KrasLA1 mice were 
greater than the additive value of DNA damage from both Xpc−/−mice and KrasLA1 mice. 
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These results suggest that XPC deficiency synergizes with KrasLA1 in inducing DNA 
damage, possibly through loss of DNA repair regulation in lung cancer development.
Induced expression of activated RAS increases ROS and DNA damage
The DNA damage detected in our studies likely came from internal insults within the cell 
because no DNA damage was observed in wild type tissues (Fig. 4). Previous studies from 
other groups have shown that oncogenic KRAS increases the level of ROS that can lead to 
DNA damage (Weinberg et al., 2010). Production of 8-deoxogunine and 4-hydroxynonenal 
(4-HNE) are important markers for oxidative stress and generation of ROS (Yang et al., 
2003; Logan et al., 2014; Zhong and Yin, 2015). We examined the level of 8-deoxogunine 
and 4-HNE in lung tissues in all four groups of mice (wild type, Xpc−/−, KrasLA1, and 
Xpc−/−KrasLA1), and found that Xpc−/−KrasLA1 mice had the highest level of 8-
deoxogunine and 4-HNE (Fig. 5). The close association of ROS with DNA damage supports 
our hypothesis that elevated production of ROS may be responsible for KrasLA1-mediated 
DNA damage during lung cancer development.
To determine whether induced expression of oncogenic RAS can induce ROS, we used lung 
epithelial BEAS-2B1 cells with inducible expression of KRASG12V. Following induction of 
KRASG12V, cells were loaded with H2DCF-DA to assess changes in the ROS level. Fig. 
6A show that ROS levels were increased by 100% at 8 hours and by 200% by 24 hours after 
KRASG12V induction. When anti-oxidant N-acetyl cysteine (NAC, 10 mmol/L) was added, 
no elevation of H2DCF-DA fluorescence was detected (Fig. 6A), confirming that induced 
expression of RASG12V did induce ROS production. We further detected DNA damage in 
these cells by the COMET assay, and found that DNA damage was significantly elevated 
following KRASG12V expression. DNA damage was observed after induction of 
KRASG12V, suggesting that ROS production occurred before DNA damage occurrence (Fig. 
6B). Confirming this mechanism, we found that NAC significantly reduced the level of 
DNA damage in KRASG12V-expressing cells. These results suggest that activated KRAS is 
sufficient to induce the cellular ROS level and subsequently to increase genomic DNA 
damage.
Taken all the data together, we have provided genetic evidence to support the critical role of 
XPC in maintenance of genomic stability in oncogenic Kras-expressing lung tissues. Our 
data demonstrate a synergy between Xpc loss and oncogenic Kras expression in promoting 
lung tumor development. We have evidence to suggest that these two genes act through 
regulation of ROS-mediated DNA damage.
DISCUSSION
Our studies have provided genetic evidence for XPC-KRAS interactions in the development 
of lung cancer. In this report, we have evidence to indicate that activated KRAS can 
stimulate the production of ROS, leading to an increase in DNA damage. Our genetic study 
supports that Xpc loss increases oxidatively damaged DNA and promotes KRAS-mediated 
lung cancer development. In our studies using cultured cells, we demonstrated that activated 
RAS increases DNA damage levels via ROS production within the cancer cell because 
antioxidant effective in decreasing both ROS and DNA damage (Fig. 6). Based on these 
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data, we propose that in addition to downstream signaling such as phosphoinositide-3-kinase 
(PI3K), protein kinase B (a serine/threonine-specific protein kinase; AKT), and mitogen-
activated protein kinase (MAPK), activated KRAS has significant effects on ROS 
production and DNA damage changed in lung cancer. Based on this model, we predict that 
strategies to enhance XPC functions may be effective in prevention of KRAS-mediated lung 
cancer development, and enhancing XPC functions may also help cancer treatment.
It is known that expression of XPC can be suppressed by p53 through transcriptional 
regulation of the XPC promoter (Adimoolam and Ford, 2002; Sengupta and Harris, 2005; 
Wu et al., 2007b; Hastak et al., 2012). In addition, the mutual interactions between XPC and 
p53 have been reported (Krzeszinski et al., 2014). Based on these data, we predict a role of 
XPC in p53-associated tumors, such as head and neck cancers and lung squamous cell 
carcinomas. Whether XPC knockout indeed plays a critical role in other cancer models 
await further experimental evidence.
It is not clear how XPC suppression promotes KRAS-driven tumor development. It is 
known that XPC is an important DNA repair gene for nucleotide excision repair pathway 
(NER), particularly global genomic DNA repair (Friedberg et al., 2000). Our results suggest 
that it is likely that the DNA damage in KRAS-mediated tumors were caused by ROS 
production. Oxidatively damaged DNA is primarily repaired by base excision repair 
processes (BER). How does XPC deficiency affect ROS-mediated DNA repair? In the last 
few years, increasing evidence indicate that XPC may be involved in repairing of oxidative 
DNA damages, either through NER or BER (Melis et al., 2011). NER is known to recognize 
and repair bulky DNA adducts and helix-distorting structures. It is known that several 
oxidative DNA lesions have structures similar to helix-distorting structures. It is thus 
feasible to speculate that NER DNA repair pathway can also repair oxidative DNA 
damages. Based on the fact that xeroderma pigmentosum group A (XPA) null mice do not 
have the similar phenotypes as the XPC null mice (Melis et al., 2008), XPC may have 
functions outside of the NER pathway. Indeed, XPC-hHR23B complex is shown to function 
as a co-factor for BER machinery to repair 8-hydroxyguanosine-related lesions (D’Errico et 
al., 2006; Melis et al., 2013). The exact molecular links between XPC and the BER 
machinery remains to be established.
At present, it is still not clear how activated RAS induces ROS production. A previous study 
indicates that activated RAS alters mitochondrial metabolism by supporting the pentose 
phosphate pathway and production of glycolytic ATP and ROS induction (Weinberg et al., 
2010). Other studies indicate that ROS production is dependent on NADPH Oxidase 1/4 and 
Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1) (Trachootham et al., 2009; Lu et al., 
2012; Ogrunc et al., 2014; Park et al., 2014; Wang et al., 2015). It is still not very clear 
whether ROS production in KrasLA1-expressing cells occurs all in mitochondria. In addition 
to DNA damage, ROS is also known to induce cell proliferation through activation of 
several cell proliferation pathways, such as MAP extracellular signal-regulated kinases 
(ERK) (Melis et al., 2011). The exact role of KrasLA1 in ROS production, DNA damage and 
the consequent tumor development remains to be delineated.
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MATERIALS AND METHODS
Animal Studies
All animal studies were approved by the Institutional Animal Care and Use Committees in 
University of Texas Medical Branch (Galveston, TX) and Indiana University (Indianapolis, 
IN). KrasLA1 mice were generously provided by the Emice Program in National Cancer 
Institute (Jackson et al., 2001), and Xpc−/−C57BL/6 mice were generously provided by Dr. 
Errol Friedberg (Cheo et al., 1997). To obtain Xpc−/−KrasLA1 mice, Xpc−/−mice were first 
mated with KrasLA1 mice, and resulting Xpc+/−KrasLA1 mice mated each other to generate 
mice with the following four genotypes: wild type, Xpc−/−, KrasLA1, and Xpc−/−KrasLA1. 
Mice were provided with normal food and water, and a 12 h light–dark cycle. All 
genotyping of mice was performed by PCR with specific primers using previously reported 
procedures (Fan et al., 2014). For survival analysis, 8 mice each from wild type, Xpc−/−, and 
KrasLA1, and 13 mice from Xpc−/−KrasLA1 were used to monitor animal viability for 60 
weeks. The low gastrointestinal part of mouse were stained with 0.1% methylene blue and 
counted under a dissecting microscope (40×). Aberrant crypt foci (ACF) were identified by 
elevated appearance from the surrounding mucosa and categorized as small (1–3 crypts per 
focus) and large ACF (4 or more crypts per focus). Total number of ACF was counted as the 
sum of the small and large number of ACF per group. Five mice were included in each 
group for ACF study.
Histology and Immunohistostaining
Histology was performed according to a previously published procedure (Fan et al., 2014) 
after paraffin embedding and hematoxylin & eosin staining. 4-HNE antibodies (Cat# 
HNE-13-M) were purchased from Alpha Diagnostic International Inc., and anti-8-oxo-dG 
(Clone 2E2) antibodies were purchased from Trevigen (Gaithersburg, MD, USA). Tissues 
were processed according to the procedures provided by the vendor. The primary antibodies 
were diluted 1:200 in 10% fetal bovine serum (FBS)/PBS at 4°C overnight for 
immunofluorescent staining. Before antibody staining, tissue sections were processed and 
blocked with 10% FBS for 3 hours to prevent non-specific staining. The secondary 
antibodies (goat anti-mouse IgG proteins labeled with Alexa Fluor 488 and 596 from 
Molecular probes) were incubated for 1h at room temperature (1:300 dilution in 10% FBS/
PBS), and the nucleus was stained with 4′,6-diamidino-2-phenylindole (2 μg/mL) before 
being viewed under microscope.
The Single Cell Gel Electrophoresis assay
The Single Cell Gel Electrophoresis assay (SCGE, also known as COMET assay) was 
performed using the Trevigen™ COMET assay kit (Trevigen, Gaithersburg, MD). Changes 
in DNA strand breaks in the freshly harvested tissues or cells were determined using neutral 
(double-strand breaks, DSBs) and alkaline (SSBs) electrophoretic conditions (Wickliffe et 
al., 2003). DNA was stained with SYBER Green and >200 cells were analyzed for each data 
point, using the COMET Assay IV v4.2 system (Perceptive Instruments, Suffolk, UK). Tail 
moment (TM) of exfoliated lung epithelial cells or lymphocytes from each group (n = 5 for 
experimental groups and n = 3 for the control group) was quantitatively measured for 
evidence of DNA damage.
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Hprt gene mutation analysis
The mutation analysis was performed according to a previous procedure using the Hprt 
cloning assay as described in Meng et al. (Meng et al., 1998). In brief, same number of cells 
from each group was grown in the presence of increasing concentrations of 6-thioguanine 
for 7–10 days. The number of surviving colonies was counted to score the mutation 
efficiency.
Cell culture
Lung epithelial BEAS-2B1 cells were generously provided by Dr. Cutis Harris (Reddel et 
al., 1993), and were cultured in DMEM with 10% fetal bovine serum (FBS). Cells with 
inducible expression of KRAS were generated with LacSwitch eukaryotic expression system 
(Strategene, La Jolla, CA), and maintained in 150 μg/mL hydromycin B. Isopropyl-1-thio-b-
D-galactopyranoside (IPTG, Life Technologies, Inc.) at 5 mmol/L was used to induce 
KRASG12V expression in the cells. N-acetyl cysteine (NAC) at 5 or 10 mmol/L was used to 
suppress the production of reactive oxygen species (ROS).
Cellular ROS analysis
2′–7′-dihydro-dichlorofluorescein diacetate (H2DCF-DA, Invitrogen Co., Carlsbad, CA, 
USA) was used to determine cellular ROS levels according to previous publications 
(Boldogh et al., 2003a, 2003b, 2005). In short, cells on microscope cover slips were placed 
in a thermo- chamber and loaded with 10 μmol/L (final concentration) H2DCF-DA for 15 
min. After induction of KRAS expression for 8, 24 and 28 hours, cells were washed with 
medium pre-warmed to 37°C and fluorescent images captured using a Photometrix 
CoolSNAP Fx digital camera mounted on a NIKON Eclipse TE 200 UV microscope. 
Fluorescence intensities of > 200 cells were determined by Metamorph™ software 
(Universal Imaging Corporation). To confirm the results in cultured cells, cells were grown 
to 70% confluence in 24 well plates and loaded with 50 μmol/L H2DCF-DA at 37°C for 30 
minutes. DCF fluorescence was recorded in an FLx800 (Bio-Tek Instruments Inc., 
Winooski, VT, USA) microplate reader (with 485 nm excitation and 528 nm emission).
Statistical analyses
Kaplan-Meier curves were generated using the SPSS program. Hprt MFs were analyzed by 
univariate ANOVA followed by post hoc mean comparisons (Bonferroni-corrected), using 
the SPSS program (SPSS, Chicago, IL). A P value < 0.05 was used to determine statistical 
significance. Comparison of two groups was done using Student’s t test (two-tail analysis), 
with a P value < 0.05 as statistically significant. BLISS independence analysis was 
performed to evaluate the synergistic effect between Xpc loss and KrasLA1 expression in 
DNA damage in lung tissues using a previously reported method (Berenbaum, 1978; Gu et 
al., 2013).
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Fig. 1. Kaplan-Meier curves of different groups of mice
Mice from four groups (8 mice each for the control, Xpc−/−, KrasLA1 groups and 13 mice 
for Xpc−/−KrasLA1 group) were monitored for 60 weeks, and their surviving time was 
recorded. The data were analyzed using Kaplan-Meier analysis.
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Fig. 2. Lung tissue morphology in different groups of mice
Lungs were sectioned and processed for Hematoxylin and eosin staining and photographs 
were taken at 100× magnification. A shows a normal lung morphology from the control 
group; B shows lung morphology from Xpc knockout mice; C shows adenoma morphology 
from KrasLA1 mice; and D shows adenocarcinoma morphology from Xpc−/−KrasLA1 mice.
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Fig. 3. Development of ACF in mice with different genetic background
The number of aberrant crypt foci (ACF) was visualized after special staining (see methods 
for details). No ACFs were observed in Xpc−/−and the normal control mice, while 
Xpc−/−KrasLA1 mice had a significantly higher number of ACF than those from 
Xpc+/+KrasLA1 mice (P value < 0.05).
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Fig. 4. DNA damage analysis in lung tissues from 2-months old mice with different genetic 
alterations
A: Fresh lung tissues from the control, Xpc−/−, KrasLA1 and Xpc−/−KrasLA1 mice were 
processed to measure DNA damage using the COMET assay. Bronchial epithelial cells were 
isolated and subjected to COMET assay. For each sample, 200 independent cells were 
evaluated. The difference between the control mice and the other three groups (Xpc−/−, 
KrasLA1 or Xpc−/−KrasLA1) were significant (with a P value <0.05; as indicated by *). Data 
from the Xpc−/−KrasLA1 mice were significantly higher than mice with a single gene 
mutation (Xpc−/−or KrasLA1) (with a P value < 0.05, indicated by **) or the sum from two 
single mutant mice. According to BLISS independence analysis, Xpc loss and KrasLA1 
expression had a more than additive effect (synergy) on induction of DNA damage.
Zhang et al. Page 15
J Genet Genomics. Author manuscript; available in PMC 2016 October 20.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 5. Detection of relative ROS in lung tissues using the amount of 4-HNE and 8-deoxogunine 
as markers
Specific antibodies to 8-deoxogunine and 4-HNE were used to detect the relative level of 
ROS in lung tissues by immunofluorescent staining (A shows 8-deoxogunine, and B shows 
4-HNE). Lung tissues from the Xpc−/−KrasLA1 mice had the highest levels of 8-
deoxogunine and 4-HNE than other groups. The control mice were shown in upper A and B. 
Representative images from Xpc−/−KrasLA1 and the control mice were shown.
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Fig. 6. The effect of induced expression of KRASG12V on ROS and DNA damage in lung 
epithelial cells
Lung epithelial BEAS-2B1 cells were engineered to express KRASG12V under the control of 
IPTG. We monitored the relative ROS level by H2DCF-DA after induced expression of 
KRASG12V for 24 hours. NAC (N-acetyl-L-cysteine, 10 mmol/L) was used to decrease the 
ROS level. A: Changes in the levels of H2DCF-DA in cultured cells under different 
conditions. B: The levels of DNA damage as shown by COMET assay. Tail moment was 
used to express level of DNA damage. In the presence of NAC, KRASG12V failed to induce 
tail moment, suggesting that KRASG12V induces DNA damage through ROS production. * 
indicates statistical significance from other groups (P value < 0.05).
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